PubMed Health⌕ Search

PubMed · 2293288

[LDL receptors].

Abstract

The low density lipoprotein receptor removes the cholesterol-carrying lipoproteins from blood. When the activity of LDL receptors is reduced, as a result of genetic or acquired abnormalities, LDL increases in blood, resulting in atherosclerosis. Heterozygote familial hypercholesterolemia (one mutant gene) is characterized by a 50% reduction of LDL receptors leading to twofold increases of LDL. In homozygote familial hypercholesterolemia (two mutant genes), there are no active LDL receptors. So very high cholesterol blood levels are observed and severe atherosclerosis ensues. FH heterozygotes can be treated with drugs that stimulate the cells to produce more LDL receptors. Because these are under negative feed-back regulation by intracellular cholesterol, depletion of intracellular cholesterol in the liver through administration of bile acid-binding resins and cholesterol synthesis inhibitors activates the synthesis of LDL receptors. The ingestion of a die rich in cholesterol and saturated fatty acids reduce the LDL receptors in the liver. This may contribute in part to the widespread occurrence of high cholesterol levels and atherosclerosis in western societies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Ducobu. 1990. [LDL receptors].. https://pubmed.ncbi.nlm.nih.gov/2293288/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.

OBJECTIVE: To determine the best time to administer statins for optimal lowering of low-density lipoprotein cholesterol (LDL-C) by reviewing the clinical evidence evaluating the chronobiologic effects of morning versus evening statin administration. DATA SOURCES: Using the MeSH terms HMG-CoA reductase inhibitors, statins, morning and evening dosing, and clinical trials, a literature review was conducted to identify articles in MEDLINE (1966-December 2006), International Pharmaceutical Abstracts (1970-December 2006), and IOWA Drug Information Systems (1985-December 2006). DATA SYNTHESIS: Seven English-language studies evaluating morning and evening statin administration were identified and evaluated. Based on the available data, simvastatin demonstrated a pronounced LDL-C percentage reduction with evening dosing. Although not statistically significant, a trend in the LDL-C percentage reduction favoring evening statin administration was noted with lovastatin, pravastatin, and rosuvastatin. Atorvastatin demonstrated similar LDL-C reduction regardless of administration time. With the exception of simvastatin, the trials comparing morning versus evening effects of statins on LDL-C have several significant methodologic shortcomings, including small sample size, lack of statistical power, and inappropriate exclusion criteria that did not include or did not mention drug-induced effects on lipids. CONCLUSIONS: There are sufficient data to support evening administration of simvastatin to achieve optimal lowering of LDL-C levels. Rigorous and robust trials are necessary to determine the best administration time to achieve optimal LDL-C lowering for lovastatin, pravastatin, rosuvastatin, atorvastatin, and fluvastatin.

Anticholesteremic Agents↗

Will torcetrapib be the next big thing in coronary heart disease risk reduction?

Scientists are seeking ways to increase high-density lipoprotein (HDL) cholesterol to lower coronary heart disease (CHD). Emerging from this search is torcetrapib, a partial inhibitor of cholesteryl ester transfer protein. Via this mechanism, cholesteryl ester is prevented from being transferred to apolipoprotein B-containing lipoproteins and is retained in HDL particles, where ostensibly it may be delivered directly to the liver for elimination. Proof that this may reduce atherosclerotic vascular disease is provided by population studies of cholesteryl ester transfer protein (CETP) deficiencies and single nucleotide polymorphisms of CETP, and experiments in animal models treated with torcetrapib. Torcetrapib effectively raises HDL cholesterol when used alone and when added to background therapy with atorvastatin. The drug appears to be well tolerated. Large surrogate and survival outcome trials are underway to document its impact on CHD.

Anticholesteremic Agents↗